Investigational drug · Phase 2
HRS-9821
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for COPD.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HRS-9821"
First trial start
2026
Jul 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-9821", any sponsor or status.
Conditions studied
As listed on its trial records.
- COPD
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-9821" as an intervention, largest first.
- Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD PatientsPivotal-lookingCompleted
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT05622864 · 106 participants · Start Jan 12, 2023 · Primary completion May 7, 2025
Drug: HRS-9821; HRS-9821 · For: Chronic Obstructive Pulmonary Disease
Sites: Chengdu, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07640451 · 90 participants (planned) · Start Jul 20, 2026 · Primary completion Oct 2026
Drug: HRS-9821 Inhalation Suspension; HRS-9821 Placebo Inhalation Suspension · For: COPD
Sites: Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07116915 · 85 participants · Start Aug 11, 2025 · Primary completion Aug 14, 2026
Drug: HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension; HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo and 1 more · For: COPD
Sites: Chengdu, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07567872 · 48 participants (planned) · Start Jul 9, 2026 · Primary completion Sep 2026
Drug: HRS-9821 Powder for Inhalation; Placebo · For: COPD
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for COPD
- SolrikitugPhase 22 trials
Uniquity One (UNI) · Eosinophilic Esophagitis (EoE), COPD
- XKH001InjectionXKH001Phase 22 trials
Zhejiang Kanova Biopharmaceutical Co., LTD · COPD, Atopic Dermatitis
- JKN2304Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease), COPD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.